Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
about
Phenobarbital induces alterations in the proteome of hepatocytes and mesenchymal cells of rat liversFluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recoveryHepatoid adenocarcinoma of the peritoneal cavity: Prolonged survival after debulking surgery and 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) therapy.HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC.Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study.A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma.The crossroads of breast cancer progression: insights into the modulation of major signaling pathways.Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study.Molecular Targets in Hepatocarcinogenesis and Implications for Therapy
P2860
Q27304855-97201417-2E99-4B45-9B09-E7F3D534F60EQ35872080-88A66AE3-D1EB-4E99-BC18-E68F29FCDE65Q36097273-B43C591C-1234-4734-92A1-F6017257CCFAQ36729450-4C0462B4-A510-4392-A393-543576DA6433Q37193150-85FEA04D-BDFB-46B7-9B17-089585B163A5Q37418248-051F3E55-5EFF-40F9-BEA4-C59C3834DD2AQ38610677-152CA943-DEC4-4365-BF3B-EDEDE297C0ECQ38996046-61B189E8-5E0D-464B-BF3D-EFD560295FCFQ40924000-7621C422-CF3C-40C9-9DBA-E2754D19550BQ44607425-BBE40D62-24C7-427F-9B0A-028145AFAAEDQ47167746-CE9E6150-3CE2-405A-90CB-F93E172C2CF4Q48140297-F040B56A-E787-4B24-8F41-1350A4F0811AQ54489566-081AFF22-B080-4973-814A-02759EF566B6Q58784853-21C4020B-2B29-4D95-A462-DA7B0CDE3BDE
P2860
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
@ast
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
@en
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
@nl
type
label
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
@ast
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
@en
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
@nl
prefLabel
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
@ast
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
@en
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
@nl
P2860
P1476
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
@en
P2093
Manabu Fukumoto
Yasunobu Matsuda
P2860
P2888
P304
P356
10.1007/S00795-011-0558-Z
P577
2011-12-17T00:00:00Z